These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 22296568

  • 1. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [Abstract] [Full Text] [Related]

  • 2. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Mar; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 3. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM, Jacobson IM.
    Antivir Ther; 2012 Mar; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [Abstract] [Full Text] [Related]

  • 4. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP, Markova AA, Calle Serrano B, Cornberg M.
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [Abstract] [Full Text] [Related]

  • 5. Future treatment of patients with HCV cirrhosis.
    Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.
    Liver Int; 2012 Feb; 32 Suppl 1():113-9. PubMed ID: 22212581
    [Abstract] [Full Text] [Related]

  • 6. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB, Jacobson IM.
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [Abstract] [Full Text] [Related]

  • 9. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Shiffman ML, Esteban R.
    Liver Int; 2012 Feb; 32 Suppl 1():54-60. PubMed ID: 22212573
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N, Zeuzem S.
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [Abstract] [Full Text] [Related]

  • 15. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
    Bacon BR, Khalid O.
    Liver Int; 2012 Feb; 32 Suppl 1():51-3. PubMed ID: 22212572
    [Abstract] [Full Text] [Related]

  • 16. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.
    Antivir Ther; 2011 Feb; 16(5):695-704. PubMed ID: 21817191
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of chronic hepatitis viral C: new associations].
    Ouzan D.
    Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.